



## NOTICE OF ANNUAL GENERAL MEETING 2020

TO BE HELD AT THE OFFICES OF:

FUTURA MEDICAL PLC  
SURREY TECHNOLOGY CENTRE, 40 OCCAM ROAD,  
GUILDFORD, GU2 7YG  
WEDNESDAY 24TH JUNE, 10AM

### THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

In the lead up to the Annual General Meeting 2020 ("AGM"), we are closely monitoring the impact of the Covid-19 virus in the United Kingdom. In light of current public health advice and "Stay at Home" measures recently introduced, which include the prohibition of public gatherings of more than two people, we do not consider that attending the AGM will fall within the "essential for work purposes" exemption of such prohibition and therefore external shareholders (**i.e. shareholders who do not also hold office as a director of the Company**) are prohibited from attending the meeting in person and if they do attempt to attend in person would be refused entry. Only the minimum number of directors who are shareholders will attend in person to ensure a quorum is present. Accordingly, so as to ensure their vote is counted at the AGM, all shareholders are asked to submit a **Form of Proxy**, instructing the Chairman of the Meeting on how they wish to vote on the proposed resolutions. Further, the Company will be providing a video conference call link to enable shareholders to follow proceedings of the meeting and to potentially ask questions relating to the proposed resolutions. Any shareholders who wish to follow the meeting by video conference should contact the Company Secretary prior to the day of the meeting at **[investor.relations@futuramedical.com](mailto:investor.relations@futuramedical.com)** in order to request video conference dial-in details and to provide the requisite identification documents.

This document should be read in conjunction with the Futura Medical plc annual report and accounts. If you are in any doubt as to the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent advisor, who, if you are taking advice in the United Kingdom, is authorised pursuant to the Financial Services and Markets Act 2000.

If you have sold or otherwise transferred all your Ordinary Shares in Futura Medical plc, please send this document to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for delivery to the purchaser or transferee. You will not receive a form of proxy for the Annual General Meeting in the post. Instead, you will receive instructions to enable you to vote electronically and how to register to do so. You may request a hard copy form of proxy directly from the registrar, Link Asset Services, on tel: 0371 664 0300.

Registered in England and Wales: No. 04206001

Registered office: Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG

## NOTICE OF ANNUAL GENERAL MEETING 2020

NOTICE IS HEREBY GIVEN that the 2020 Annual General Meeting (AGM) of Futura Medical plc (the “Company”) will be held at their Head Office, Surrey Technology Centre, 40 Occam Road, Guildford, GU2 7YG on Wednesday 24 June 2020, at 10.00am (the “Meeting”), for the purpose of considering and, if thought fit, pass the following resolutions :

Resolutions 1 to 5 will be proposed as ordinary resolutions and Resolutions 6 to 8 will be proposed as special resolutions.

1. To receive and adopt the annual report of the directors and the financial statements for the financial year ended 31 December 2019 and the report of the appointed auditors thereon. (Resolution 1)
2. To re-elect Jonathan Freeman as a Director of the Company, who retires by rotation in accordance with the Company’s articles of association. (Resolution 2)
3. To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company. (Resolution 3)
4. To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company. (Resolution 4)

### 5 AUTHORITY TO ALLOT SHARES

That the Directors be and are hereby generally and unconditionally authorised in accordance with Section 551 of the Companies Act 2006 to issue and allot ordinary shares in the capital of the Company and grant subscription and conversion rights over ordinary shares in the capital of the Company as contemplated by sections 551(1)(a) and (b) of the Companies Act 2006 respectively up to a maximum aggregate nominal amount of £162,116 to such persons at such times and on such terms as they think proper, provided that this authority shall expire on the date of the next AGM in 2021 (or, if earlier, on 24 September 2021), unless and to the extent that such authority is renewed, varied, revoked or extended prior to such date, except that the Company may before such expiry make an offer or agreement which would or might require relevant securities to be allotted in pursuance of such offer or agreement as if the authority conferred hereby had not expired. (Resolution 5)

### SPECIAL RESOLUTIONS

#### 6 DISAPPLICATION OF PRE-EMPTION RIGHTS

That, subject to the passing of Resolution 5 set out above, the Directors be and are hereby given power pursuant to Sections 570(1) and 573 of the Companies Act 2006 to allot equity securities (as defined in Section 560(1) of the Companies Act 2006) for cash pursuant to the authorisation conferred by that resolution, as if Section 561 of the Companies Act 2006 did not apply to any such allotment, provided that such authority be limited:

- (a) To the allotment of equity securities where such securities have been offered (whether by rights issue, open offer or otherwise) to the holders of ordinary shares in the capital of the Company made in proportion (as nearly as may be) to their existing holdings but subject to the Directors having a right to make such exclusions or other arrangements in connection with the offering as they may deem necessary or expedient:
  - i To deal with equity securities representing fractional entitlements; and
  - ii record dates or legal, regulatory or practical difficulties which may arise under the laws of, or the requirements of any regulatory body or stock exchange in, any territory or any other matter whatsoever; and
- (b) the allotment of equity securities for cash otherwise than pursuant to paragraph (a) of this resolution up to an aggregate nominal value of £24,563 such authority to expire at the conclusion of the next Annual General Meeting of the Company (or, if earlier, on 24 September 2021), unless previously revoked or varied by the Company (save that the Company may before such expiry make any offer or agreement that would or might require equity securities to be allotted, after such expiry and the Directors may allot equity securities, or sell treasury shares in pursuance of any such offer or agreement as if the power conferred hereby had not expired). (Resolution 6)

## **7 DISAPPLICATION OF PRE-EMPTION RIGHTS IN RESPECT OF AN ADDITIONAL 5% OF THE COMPANY'S ISSUED SHARE CAPITAL**

To resolve that, subject to the passing of Resolution 6 set out above, the Directors be and are hereby given power, in addition to any authority granted under Resolution 6(b) above and, pursuant to Sections 570(1) and 573 of the Companies Act 2006 to allot equity securities (as defined in Section 560(1) of the Companies Act 2006) for cash pursuant to the authorisation conferred by that resolution, as if Section 561 of the Companies Act 2006 did not apply to any such allotment, provided that such authority be:

- (a) limited to the allotment of equity securities up to a nominal amount of £24,563; and
- (b) used only for the purposes of financing (or refinancing, if the authority is to be used within six months after the original transaction) a transaction which the Directors of the Company determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice, such authority to expire at the conclusion of the next Annual General Meeting of the Company (or, if earlier, on 24 September 2021), unless previously revoked or varied by the Company (save that the Company may before such expiry make any offer or agreement that would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if the power conferred hereby had not expired). (Resolution 7)

## **8 ADOPTION OF NEW ARTICLES OF ASSOCIATION**

That the Articles of Association contained in a document produced to the meeting and signed by the Chief Executive Officer for the purposes of identification be approved and adopted as the New Articles of Association of the Company in substitution for, and to the exclusion of, the existing Articles of Association.

By order of the Board

**Angela Hildreth**

**Company Secretary**

Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG

Registered in England and Wales: No. 04206001

18th May 2020

## NOTICE OF ANNUAL GENERAL MEETING NOTES:

The following notes explain your general rights as a shareholder and your right to attend and vote at this Meeting or to appoint someone else to vote on your behalf.

1. To be entitled to attend and vote at the Meeting (and for the purpose of the determination by the Company of the number of votes they may cast), shareholders must be registered in the Register of Members of the Company at close of trading on 22 June 2020. Changes to the Register of Members after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the Meeting.
2. In light of current public health advice and “Stay at Home” measures Shareholders are not permitted to attend the meeting and so all Shareholders are asked to cast their vote electronically or by post via proxy, instructing the Chairman of the Meeting on how they wish to vote on the proposed.
3. Shareholders are entitled to appoint another person as a proxy to exercise all or part of their rights to attend and to speak and vote on their behalf at the Meeting. A shareholder may appoint more than one proxy in relation to the Meeting provided that each proxy is appointed to exercise the rights attached to a different Ordinary Share or Ordinary Shares held by that shareholder. A proxy need not be a shareholder of the Company. Shareholders voting by proxy are asked to only appoint the Chairman of the Meeting as their proxy as given the current public health advice and “Stay at Home” measures, only the Chairman and 1 other will be present 1 person at the meeting.
4. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company’s Register of Members in respect of the joint holding (the first named being the most senior).
5. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the Meeting.
6. In light of current public health advice and “Stay at Home” measures Shareholders are not permitted to attend the meeting and so all Shareholders are asked to cast their vote as follows:
  - by logging on to [www.signalshares.com](http://www.signalshares.com) and following the instructions; if you need help with voting online please contact our registrar, Link Asset Services (previously called Capita), on 0371 664 0391 if calling from the UK, or +44 (0)371 664 0391 if calling from outside of the UK, or email Link at [shareholderenquiries@linkgroup.co.uk](mailto:shareholderenquiries@linkgroup.co.uk).
  - in the case of CREST members, by utilising the CREST electronic proxy appointment service in accordance with the procedures set out below. In order for a proxy appointment to be valid a form of proxy must be completed.
  - by requesting a hard copy form of proxy directly from the registrars, Link Asset Services, on Tel: 0371 664 0391. Calls are charged at the standard geographical rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 – 17:30, Monday to Friday excluding public holidays in England and Wales.
  - in any case in order to be valid the form of proxy must be received by Link Asset Services at 34 Beckenham Road, Beckenham, Kent BR3 4TU by 10.00am on 22 June 2020.
7. If you return more than one proxy appointment, either by paper or electronic communication, the appointment received last by the registrar before the latest time for the receipt of proxies will take precedence. You are advised to read the terms and conditions of use carefully. Electronic communication facilities are open to all shareholders and those who use them will not be disadvantaged.
8. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the Meeting (and any adjournment of the Meeting) by using the procedures described in the CREST Manual (available from [www.euroclear.com/site/public/EUI](http://www.euroclear.com/site/public/EUI)). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

9. In order for a proxy appointment or instruction made by means of CREST to be valid, the appropriate CREST message (a “CREST Proxy Instruction”) must be properly authenticated in accordance with Euroclear UK & Ireland Limited’s specifications and must contain the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer’s agent (ID RA10) by 10.00am on 22 June 2020. For this purpose, the time of receipt will be taken to mean the time (as determined by the timestamp applied to the message by the CREST application host) from which the issuer’s agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
10. CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & Ireland Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed (a) voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
11. Any corporation which is a shareholder can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a shareholder provided that no more than one corporate representative exercises powers in relation to the same shares.
12. As at 15 May 2020 (being the latest practicable business day prior to the publication of this Notice), the Company’s ordinary issued share capital consists of 245,629,926 Ordinary Shares, carrying one vote each. Therefore, the total voting rights in the Company as at 15 May 2020 are 245,629,926.
13. Under Section 527 of the Companies Act 2006, shareholders meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company’s financial statements (including the auditor’s report and the conduct of the audit) that are to be laid before the Meeting; or (ii) any circumstances connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual financial statements and reports were laid in accordance with Section 437 of the Companies Act 2006 (in each case) that the shareholders propose to raise at the relevant meeting. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with Sections 527 or 528 of the Companies Act 2006. Where the Company is required to place a statement on a website under Section 527 of the Companies Act 2006, it must forward the statement to the Company’s auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the Meeting for the relevant financial year includes any statement that the Company has been required under Section 527 of the Companies Act 2006 to publish on a website.
14. Any shareholder attending the Meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business being dealt with at the Meeting but no such answer need be given if: (a) to do so would interfere unduly with the preparation for the Meeting or involve the disclosure of confidential information; (b) the answer has already been given on a website in the form of an answer to a question; or (c) it is undesirable in the interests of the Company or the good order of the Meeting that the question be answered.
15. In light of current public health advice and “Stay at Home” measures the Company is not able to make available for inspection copies of the Directors’ letters of appointment or service contracts which would ordinarily be available for inspection prior to and at the meeting.

16. You may not use any electronic address (within the meaning of Section 333(4) of the Companies Act 2006) provided in either this Notice or any related documents (including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.

A copy of this Notice, and other information required by Section 311A of the Companies Act 2006, can be found on the Company's website at [www.futuramedical.com](http://www.futuramedical.com).

A copy of the proposed new articles of association for the Company can be under current constitutional documents on the Company's website at [www.futuramedical.com/investor-centre/corporate-documentation](http://www.futuramedical.com/investor-centre/corporate-documentation). If you have not elected to receive electronic communications and wish to receive a hard copy of the proposed new Articles then please contact [investor.relations@futuramedical.com](mailto:investor.relations@futuramedical.com) and a hard copy will be sent to you.

## INFORMATION ON RESOLUTIONS

### RESOLUTION 1: TO RECEIVE AND ADOPT THE ANNUAL REPORT AND ACCOUNTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019

The Company is required to present the Directors' report, audited financial statements and the independent auditor's report at a general meeting.

### RESOLUTION 2: RE-ELECTION OF DIRECTORS

In accordance with the Articles of Association of the Company Jonathan Freeman will retire by rotation and stand for re-election.

Jonathan Freeman was appointed to the Board in 2003.

Biographical details of Jonathan Freeman are shown on page 37 of the annual report and accounts and on the Company's website.

### RESOLUTIONS 3 AND 4: RE-APPOINTMENT OF THE AUDITOR AND APPROVAL OF ITS REMUNERATION

At every general meeting at which accounts are presented to shareholders, the Company is required to appoint an auditor to serve from the end of the meeting until the next such meeting. The Board is proposing the appointment of Grant Thornton UK LLP ("GTUK") as the Company's auditor. The Company's Audit Committee has reviewed GTUK's effectiveness and recommends its appointment. Resolution 3 proposes the appointment of GTUK as the Company's auditor to hold office until the next Annual General Meeting of the Company. Resolution 4 authorises the Directors to determine its remuneration. The Directors have delegated the responsibility of fixing the auditor's remuneration to the Audit Committee of the Board.

### RESOLUTION 5: AUTHORITY TO ALLOT SECURITIES

The Directors may allot shares and grant rights to subscribe for, or convert any security into, shares only if authorised to do so by the shareholders. Resolution 5 proposes granting the Directors authority to allot shares and grant rights to subscribe for, or convert any security into, shares up to an aggregate nominal amount of £162,116. The nominal amounts to which this authority relates represent approximately 33% of the issued ordinary share capital of the Company as at 15 May 2020. The authority will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, on 24 September 2021. It is the Directors' intention to seek renewal of this authority annually. The Directors have no present intention of exercising this authority. The Company does not hold any shares in treasury.

### RESOLUTION 6: DISAPPLICATION OF PRE-EMPTION RIGHTS

Resolution 6 gives the Directors the power, in certain limited circumstances, to allot equity securities for cash without first being required to offer such shares to the existing shareholders in proportion to their existing holdings. Apart from in connection with rights issues and other pre-emptive offers, the power will be limited to the allotment of equity securities for cash up to an aggregate nominal value of £24,563 (being approximately 5% of the issued ordinary share capital of the Company as at 15 May 2020, the latest practicable date prior to publication of this Notice). The Directors will have due regard to the Pre-Emption Group's Statement of Principles published on 12 March 2015 (the "Statement of Principles") in relation to any exercise of this power, in particular to the requirement for advance consultation and explanation before making any non-pre-emptive cash issue pursuant to this resolution which exceeds 7.5% of the share capital in any rolling three-year period.

The authority will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, on 24 September 2021. It is the Directors' intention to seek renewal of this authority annually. It is standard practice for most United Kingdom companies to propose this resolution each year.

## **RESOLUTION 7: DISAPPLICATION OF PRE-EMPTION RIGHTS IN RESPECT OF AN ADDITIONAL 5% OF THE COMPANY'S ISSUED SHARE CAPITAL**

Resolution 7 also gives the Directors the power, in certain limited circumstances, to allot equity securities for cash without first being required to offer such shares to the existing shareholders in proportion to their existing holdings. The disapplication of pre-emption rights in respect of a further 5% of the Company's issued share capital in addition to the authority proposed to be granted pursuant to Resolution 7 reflects the guidance from the Statement of Principles and the Guidance issued by the Pre-Emption Group on 5 May 2016. The power will be limited to the allotment of equity securities for cash up to an aggregate nominal value of £24,563 (being approximately 5% of the issued ordinary share capital of the Company as at 15 May 2019, the latest practicable date prior to publication of this Notice) provided that the authority can only be used in connection with the financing or refinancing of an acquisition or specified capital investment (within the meaning of the Statement of Principles). Any such refinancing must be within six months of the original transaction. The Directors will have due regard to the Statement of Principles in relation to any exercise of this power. The authority will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, on 24 September 2021. It is the Directors' intention to seek renewal of this authority annually.

## **RESOLUTION 8: ADOPTION OF NEW ARTICLES OF ASSOCIATION FOR THE COMPANY ("NEW ARTICLES")**

The Board has taken the decision to seek approval for the adoption of new articles of the Company to allow it to more efficiently deal with general meetings, including annual general meetings, in circumstances where physical meetings are prevented for example due to extreme events such as the current circumstances with COVID-19. The proposed changes provide new definitions of physical, electronic and hybrid meetings to allow maximum flexibility in the holding of shareholder meetings in times when gatherings of large groups of people are prohibited or limited in scope, and therefore allowing for remote attendance and the casting of votes via virtual meetings. As such, the New Articles are being adopted to include the possibility of holding a general meeting on an electronic platform and therefore allowing shareholders to attend and vote remotely, and also grant the Board the power to determine whether a general meeting will be a physical, electronic or hybrid meeting. The changes in the proposed New Articles, are limited to those which are necessary to grant the power to hold meetings (wholly or partially) on electronic platforms and permit attendance and voting (wholly or partially) on a virtual basis. The Board wishes to confirm that its wish is at present to hold physical meetings, including future AGMs, whenever reasonably possible. A copy of the draft New Articles, setting out the proposed changes to the existing Articles, are available by clicking on the link New proposed Articles of Association under current constitutional documents on the Company's website at [www.futuramedical.com/investor-centre/corporate-documentation](http://www.futuramedical.com/investor-centre/corporate-documentation). If you have not elected to receive electronic communications and wish to receive a hard copy of the proposed new Articles then please write to [investor.relations@futuramedical.com](mailto:investor.relations@futuramedical.com) and a hard copy will be sent to you.

